Condition: Systemic Lupus Erythematosus · Sponsor: AstraZeneca
The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in LLDAS at enrolment. Patients will be naïve to any prior conventional immunosuppressant including prior biologic therapy at enrolment. The study will also employ a tapering protocol for a systematic approach to GC tapering, seeking to understand better the proportion of patients in remission who can successfully withdraw chronic GC completely.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Anniston, Alabama, United States | Withdrawn |
| Research Site | Birmingham, Alabama, United States | Not Yet Recruiting |
| Research Site | Phoenix, Arizona, United States | Not Yet Recruiting |
| Research Site | Tucson, Arizona, United States | Not Yet Recruiting |
| Research Site | Fontana, California, United States | Not Yet Recruiting |
| Research Site | La Jolla, California, United States | Not Yet Recruiting |
| Research Site | La Palma, California, United States | Not Yet Recruiting |
| Research Site | Menifee, California, United States | Recruiting |
| Research Site | San Leandro, California, United States | Recruiting |
| Research Site | Temecula, California, United States | Recruiting |
| Research Site | Brandon, Florida, United States | Not Yet Recruiting |
| Research Site | Miami, Florida, United States | Not Yet Recruiting |
+ 91 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07430306